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Structure and substrate recognition of the Bottromycin 
maturation enzyme BotP 
Greg Mann,[a, +] Liujie Huo,[b, +] Sebastian Adam,[c] Brunello Nardone,[a] Jeremie Vendome,[d, e] Nicholas 
James Westwood,[a] Rolf Müller,[f] Jesko Koehnke*[c] 
 
Abstract: The bottromycins are a family of highly modified peptide 
natural products displaying potent antimicrobial activity against 
Gram-positive bacteria including methicillin-resistant 
Staphyloccoccus aureus. Bottromycins have recently been shown to 
be ribosomally synthesized and post-translationally modified 
peptides (RiPPs). Uniquely amongst RiPPs the precursor peptide 
BotA contains a C-terminal follower, rather than the canonical N-
terminal leader sequence. We report the structural and biochemical 
characterization of BotP, a leucyl-aminopeptidase like enzyme from 
the bottromycin pathway. We demonstrate that BotP is responsible 
for the removal of the N-terminal methionine from the precursor 
peptide. The crystal structures of apo BotP and of BotP in complex 
with Mn
2+
 allowed us to model a BotP/substrate complex and to 
rationalize substrate recognition. Our data represent the first step 
towards targeted compound modification to unlock the full antibiotic 
potential of bottromycin. 
Introduction 
Bottromycins have recently been identified as ribosomally 
synthesized and post-translationally modified peptides (RiPPs) – 
a growing class of natural products[1]. Like other RiPPs, 
bottromycins are derived from a core peptide, which is part of a 
larger precursor peptide (BotA). It is encoded for by a structural 
gene, which undergoes extensive post-translational 
modifications (PTMs) by a series of enzymes to become the final 
product[1] (Figure 1). Uniquely amongst RiPPs, BotA contains a 
C-terminal follower sequence, in place of an N-terminal leader 
sequence, which is thought to be important for stability and 
recognition of PTM enzymes[1,2]. The genes responsible for 
bottromycin biosynthesis, including that of the precursor peptide 
(botA) and the necessary tailoring enzymes, are localized within 
a single biosynthetic gene cluster[3,4] (Figure 1). Bottromycin 
maturation involves multiple methylation and proteolysis steps, 
amidine macrocycle and thiazole heterocycle formation, and C-
terminal decarboxylation[4–6] (Figure 1). 
Previously, using gene deletion experiments and subsequent 
product formation analysis, only the unusual set of methyl 
transferases had been assigned to their function in bottromycin 
biosynthesis[3,4,7]. Now an order for these transformations as well 
as functions for the modifying enzymes have very recently been 
proposed based on metabolomics data of an engineered 
bottromycin pathway[5]. In that analysis BotP appears to be the 
first enzyme of the pathway to act on BotA.  
BotP, shares sequence homology with a number of M17 leucine 
aminopeptidases (LAPs) from various organisms[3,6] (Figure S1). 
These metal dependent proteases hydrolyse peptide substrates 
with N-terminal leucine and methionine residues[8]. The function 
of LAPs in nature has evolved beyond ordinary roles in cell 
maintenance: degrading peptides released by endoproteases 
and the proteasome into amino acids. They are implicated in 
various additional biological functions, including the processing 
of bioactive peptides, vesicular trafficking, transcriptional 
regulation, mediating site-specific recombination, and as viral 
and toxin receptors[8,9]. 
As a putative LAP it is predicted that BotP facilitates the removal 
of methionine from the N-terminus of BotA[3]. Here we report the 
first biochemical and structural characterization of a PTM 
enzyme from the bottromycin biosynthetic pathway. The crystal 
structures of apo BotP and of BotP in complex with Mn2+ allowed 
us to build a BotP/substrate peptide model and determine the 
BotP residues involved in substrate recognition. Incubation of 
BotP with recombinantly produced BotA shows that this enzyme 
is responsible for the removal of the N-terminal methionine of 
BotA. The predictions based on our enzyme/substrate model 
were then tested in biochemical assays using peptide substrates. 
Results and Discussion 
Overall structure of BotP 
BotP was purified as described in the materials and methods 
section and subjected to crystallisation trials using commercially 
available sparse-matrix screens. Crystals grew after three days 
in a number of conditions, but were too small to yield good 
diffraction. Following optimization, the best crystals were 
selected and a data set was collected at Diamond to 1.76 Å 
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(PDB 5LHJ). The structure was determined using molecular 
replacement (ensemble of multiple search models). The data 
collection and refinement statistics can be found in Table 1. The 
crystal contained one monomer in the asymmetric unit, which 
like other M17 LAPs is one subunit of a hexamer (Figure 2A). 
Analysis with PISA (software that enables the exploration of 
macromolecular interfaces)[10]  suggests this hexameric 
assembly to be biologically relevant, which is consistent with 
previous observations in homologous structures[9,11,12]. A BotP 
monomer consists of a small N-terminal domain (residues 35-
163), and a larger pseudo-spherical C-terminal catalytic domain 
(residues 164-499), creating a characteristic ‘comma’ shape 
(Figure 2B). The overall structure of BotP is highly similar to 
other M17 LAPs, and structural comparison with the recently 
characterized XoLAP[11] (PDB ID 3JRU) shows a Cα root mean 
square deviation (RMSD) of 1.61 Å over 339 residues. 
Superimposing the two structures in PyMOL reveals that while 
the two C-terminal domains are highly similar, the smaller N-
terminal domains show slightly more deviation, which is a 
common observation within the protein family (Figure S2). 
Putative catalytically important residues of BotP (based on 
alignments with other LAPs) are completely conserved in both 
sequence and structure (Figure S1). Within this cluster of active 
site-residues a chloride ion is in place of the bicarbonate ion 
commonly found in LAPs.  However, the two divalent metal ions 
observed in LAPs are absent in this structure despite 
conservation of all the ligating residues (Figure S3). 
 
Biochemical characterization of BotP 
Recombinantly produced precursor peptide BotA (100 μM) was 
incubated with BotP (5 μM) at 37 °C overnight and proteolysis 
was monitored by LC-MS (Figure S4). No activity could be 
detected, which we believed to be a result of the absence of 
metal ions (as seen in the structure). Typical metals found in 
active LAPs include Zn2+, Mn2+ Co2+ and Mg2+ ions[8,13]. The 
proteolysis reaction was repeated with a truncated version of 
BotA in the presence of 100 μM of each metal ion and reaction 
progress was monitored over time using LC-MS (Figure 3A). 
Addition of Co2+ conferred the highest activity with complete 
substrate turnover observed after just 1 h (Figure 3A, S4). BotP 
was less active in the presence of Mn2+, processing ~ 90 % of 
the substrate in 12 h, while almost no activity was detected with 
Mg2+ and Zn2+ ions (Figure 3A). 
 
Metal binding of BotP 
Given the partial and full restoration of activity in the presence of 
Mn2+ and Co2+ respectively we sought to determine the 
structures of BotP in complex with these ions. Soaking optimized 
BotP apo crystals in the presence of MnCl2 was detrimental to 
the diffraction quality of the crystals. Consequently BotP was 
pre-incubated with MnCl2 overnight on ice, prior to crystal 
screening. Crystals of putative BotP-Mn2+ complexes grew in 
conditions different to the apo crystals. Attempts to obtain a 
BotP-Co2+ complex via both crystal soaking and pre-incubation 
were unsuccessful. The putative BotP-Mn2+ crystals were back-
soaked prior to freezing to remove any unbound Mn2+ ions. 
These crystals were then used in an X-ray fluorescence scan to 
confirm the presence of Mn2+ in the crystals. The recorded 
spectrum (Figure S5) is congruent with the presence of Mn2+ in 
the BotP-Mn2+ crystals. Data for these crystals was collected at 
the SLS at the Mn-edge and the complex structure solved using 
Mn-SAD (Manganese Single-wavelength Anomalous Diffraction, 
PDB 5LHK). As expected both putative metal binding sites were 
occupied with Mn2+ (Figure 2C). This time a bicarbonate ion was 
found in place of the chloride ion in the apo structure.  
 
Substrate recognition by BotP 
A common property of enzymes from RiPP natural product 
biosynthesis is their broad substrate tolerance, enabling the 
same enzymes to synthesize multiple products[14,15]. Since co-
crystallization of BotP with substrate peptides or full-length BotA 
proved intractable due to slow crystal growth and fast enzymatic 
turnover, we used modeling to provide insights into substrate 
specificity. The hexameric assembly of BotP prevents accurate 
modeling of BotA beyond residue 4, which led us to model the 
complex of BotP with the sequence MGPV (P1-P3’ in protease 
nomenclature (Figure 4A, S6); the enzyme pocket binding the 
P1 residue is referred to as S1 and so forth.). We did not find 
any indication that substrate residues beyond MGPV are 
involved in BotP binding in silico, with the C-terminal Val residue 
only marginally contributing to binding. To test this 
experimentally, we performed a competition assay using BotA 
and truncated BotA (MGPVV). BotA gets processed in the same 
manner but ~4-fold faster than the truncated version (Figure 
S4C). It could not be determined whether this difference in rate 
is the result of (non)-specific substrate-enzyme interactions or 
simply a thermodynamic effect of the substrate size. 
Nevertheless our model adequately addresses the substrate 
specificity, which primarily concerns the first three residues of 
the core peptide. We verified this claim by our subsequent 
biochemical experimentation. The long and narrow S1 pocket is 
very well suited to accommodate methionine residues with an 
extended side-chain. The P1 methionine residue makes 
hydrophobic contact with Thr375 and forms a hydrogen bond 
with Thr373 (Figure 4B). Additionally it partakes in the extensive 
hydrogen-bonding network involving the two Mn2+ ions (Figure 
4B). The S1 pocket might also allow the binding of Gly, Ala and 
Cγ-branched amino acids. Residues branched at the Cβ cannot 
fit into the pocket. To test this hypothesis we incubated BotP 
with Co2+ ions and peptides MGPVV (wild-type), LGPVV and 
IGPVV. The LGPVV peptide was processed slowly (compared to 
wild-type) and complete turnover was observed after 6 h (Figure 
3B). However the IGPVV peptide was only partially cleaved by 
BotP after 12 h, indicating it is a very poor substrate. The S1’ 
pocket is particularly narrow and the glycine forms hydrogen 
bonds with the carbonyl of Leu374 and the side-and main-chain 
of Ser376. At first glance our model would only allow for glycine 
residues. However, assuming a slight rotation of the BotP 
Asn301 side-chain, larger residues could also be 
accommodated including Val or Ile. We sought to test this 
hypothesis by attempting to cleave MAPVV and MIPVV (Figure 
3C). Both changes were accepted, but cleavage progressed 
much faster with the Ala substitution. To probe substrate 
tolerance at this position further an additional 16 substrate 
peptides were tested (Figure S7). As expected Ser was 
processed as well as Ala and bulkier amino acids and those with 
longer side-chains were processed more slowly. A surprise was 
Lys in the P1’ position, which still gets processed at half the rate 
of Ala/Ser. We believe this to be the result of Lys’s 
extraordinarily flexible side-chain. The S2’ and S3’ pockets 
provide an interesting insight into substrate recognition. BotP 
residues Asn344 and Asp440 block most of the S3’ pocket 
(Figure 4B). These residues are usually Ala and Gly residues, 
respectively, in other LAPs. This is consistent with P2’ being a 
proline residue, which introduces an elbow into the substrate 
peptide, leading it away from the enzyme’s surface. The Pro 
residues make hydrophobic interactions with His341, Asn344 
and Asp440. Substitution of P2’ Pro to Ala (MGAVV) was 
tolerated by BotP but at a rate slower compared with the wild-
type sequence (Figure 3D). 
Conclusions 
The bottromycins are members of the ever-growing ribosomal 
and post-translationally modified peptide synthesis family of 
natural products. They are synthesized as a precursor peptide, 
which undergoes extensive enzymatic (and possibly non-
enzymatic) post-translational modification to become the final 
product. At present much of the detail regarding the enzymatic 
transformations remains unknown. One essential modification is 
ChemBioChem 10.1002/cbic.201600406
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the removal of the N-terminal methionine from the precursor 
peptide BotA. Sequence homology with a number of known 
leucyl aminopeptidases indicated BotP as the enzyme 
responsible for this modification. 
Recombinant BotP isolated from E. coli was initially inactive due 
to the absence of divalent metal ions as cofactors. Addition of 
Mn2+ or Co2+ restored activity. Turnover was faster with Co2+ 
than with Mn2+. There has been a long debate regarding the 
identity of the divalent metal ions bound at the active sites of 
LAPs[8]. While this study identifies Co2+ as the ion giving the 
highest relative level of activity, we cannot discern which metal 
ions (or combinations of metal ions) are preferred in the natural 
producer of bottromycins. Nevertheless it would seem that Co2+ 
would be a good choice for future in vitro studies. 
Most PTM enzymes from RiPP pathways act on the leader 
peptide or protease recognition elements outside the core 
peptide. This separation of recognition from catalysis results in a 
large tolerance for substrate changes by the respective enzymes. 
In fact, the sequence of several core peptides can essentially be 
hypervariable. In the case of bottromycins, the absence of an N-
terminal protease site outside the core peptide could be 
interpreted as a severe restriction on the combinatorial 
possibilities for engineered substrates. However, it appears that, 
perhaps in an effort to limit this restriction, BotP seems to have 
evolved to recognize and bind to just 3 residues with binding 
pockets S3’ partially, and S4’ and S5’ completely, inaccessible, 
compared with other LAPs. Even for the binding pockets that are 
available, BotP is able to at least tolerate drastic single amino 
acid changes, although processing progresses more slowly. This 
may bode well for future engineering of the pathway, since BotP 
activity is essential to liberate the N-terminus of BotA, thus 
making it available for macrocyclisation. We would like to note 
that BotP processes its substrate significantly faster than other 
RiPP proteases. We believe this to be a reflection of its relative 
position in the biochemical cascade – normally RiPPs proteases 
remove the leader and it has been suggested that they are 
deliberately slow to avoid cleavage before the PTMs are 
completed. BotP has no such restrictions. In fact, by being the 
first enzyme of the pathway short processing times are essential 
for efficient bottromycin biosynthesis. 
Bottromycins exhibit promising antimicrobial activity, owed to a 
unique molecular scaffold and a novel biological target. Their 
biosynthesis requires diverse chemical transformations. The 
better understanding of BotP as a PTM enzyme of this pathway 
is a first step towards structure guided and targeted compound 
modification in vitro and in vivo to unlock the bottromycins’ full 
antibiotic potential. 
Experimental Section 
Protein cloning, expression and purification 
Full-length botP was cloned into pEHISMBPTEV and expressed 
in E. coli BL21 DE3 cells grown in auto-induction medium at 
20 °C for 48 h[16,17]. Cells were harvested by centrifugation (4000 
g, 4 °C, 15 min) and resuspended in lysis buffer (500 mM NaCl, 
20 mM imidazole, 20 mM Tris pH 8.0, 3 mM β-mercaptoethanol 
(BME)) supplemented with cOmplete EDTA-free protease 
inhibitor tablets (Roche) and DNase (0.4 mg g-1 wet cells, 
Sigma). Cell suspension was lysed via passage through a cell 
disruptor (30 kpsi, Constant Systems Ltd), and the cell debris 
were removed by centrifugation (40 000 g, 4 °C, 20 min).  The 
supernatant was filtered through a 0.45 μm filter and applied to a 
HF-Ni-NTA (GE Healthcare) pre-equilibrated in lysis buffer.  The 
protein was eluted in lysis buffer supplemented with extra 
imidazole (250 mM). The protein eluent was passed over a 
desalting column (16/10 GE Healthcare) into “low imidazole, low 
salt” buffer (150 mM NaCl, 20 mM imidazole, 20 mM Tris pH 8.0, 
3 mM BME) and subsequently incubated with TEV protease at 
room temperature for 2 h to remove His6-tagged-MBP.  Digested 
protein was loaded onto a HF-Ni-NTA, and the flow through was 
collected. A homogenous and pure sample as obtained via 
passage down a Superdex 200 gel filtration column (GE 
Healthcare) pre-equilibrated in gel filtration buffer (150 mM NaCl, 
10 mM HEPES pH 7.4, 1 mM TCEP). Protein purity was 
assessed by SDS-PAGE and integrity confirmed by MS. 
Full-length, codon-optimized botA was constructed from 
synthetic primers using PCR and cloned into the 
pEHISSUMOTEV plasmid to introduce a TEV cleavable SUMO 
tag. Expression and purification were performed as described for 
BotP. 
 
X-ray Crystallography 
Crystals of apo-BotP were obtained in PEG 3350 (20 % (w/v)) 
and sodium malonate pH 7.0 (0.24 M). Crystals of BotP-Mn2+ 
complex were obtained in PEG 4000 (10 % w/v)), MES pH 6.5 
(0.1 M). Diffraction data for apo-BotP and BotP-Mn2+ crystals 
were collected at Beamlines I04-1 (Diamond light source) and 
X06DA (Swiss Light Source), respectively. Data was processed 
using Xia2 and the apo structure solved using PHASER 
Molecular Replacement using an ensemble of multiple search 
models generated in Ensemblr[18–20]. The Mn2+-structure was 
solved using PHENIX autosol with autobuild[21,22]. The models 
were manually rebuilt with COOT and refined using PHENIX[21,22] 
and Refmac5[23]. The structure was validated using MolProbity 
and all images were presented using PyMOL[24,25]. Interaction 
diagrams were created using Ligplot[26]. 
 
Modeling of Substrate Complex 
The peptide MGPV was modeled in the catalytic pocket of the 
reported structure of BotP using the crystal structure of the small 
peptidomimetic molecule Ubenimex (a.k.a. Bestatin) bound in 
the catalytic site of the zinc-dependent leucine aminopeptidase 
from Pseudomonas putida ppLAP (PDB code 3H8G, chain A) as 
a template. Specifically, the structure of Pseudomonas putida 
ppLAP bound to Ubenimex was aligned to our structure of BotP, 
and the coordinates of chosen atoms of Ubenimex were used as 
initial position for certain P1, P1’ and P2’ backbone atoms. Initial 
coordinates for the remaining atoms of P1, P1’, P2’ and P3’ 
were generated using the build internal coordinates function in 
Charm (version c32a2). The structure of the peptide was then 
minimized in the context of the BotP catalytic site, using 50 
steps of steepest descent followed by 1000 steps of conjugate 
gradient minimization, with a position constraint of 10 kcal mol-1 
on all BotP heavy atoms. Since two peptidomimetic inhibitors of 
leucine aminopeptidase, namely Ubenimex and Leucine p-
nitroaminal, were previously reported to bind LAP with their N-
terminus in a deprotonated form (NH2), both the protonated 
(NH3
+) and deprotonated (NH2) forms of the MGPV peptide were 
modeled following the protocol described above. Consistent with 
what was observed for the two peptidomimetic inhibitors, the 
deprotonated form bound much more favorably in the BotP site, 
the NH2 group notably coordinating the second zinc ion. The 
model with a deprotonated N-terminus is presented in the article. 
 
Peptide Synthesis 
The solid-phase synthesis of the peptides was carried out on a 
Rink-amide PEG resin (0.45 mmol g-1) purchased from Meck-
Millipore. Fmoc amino acids and all other reagents were 
purchased from Sigma-Aldrich and were used without any 
further purification. Syntheses were performed manually on a 
0.023 mmol scale. Amino acids were coupled using a 5-fold 
excess (0.12 mmol). A solution of 0.5 M HBTU (0.12 mmol, 46 
mg) in DMF (1mL) was added to the Fmoc protected amino acid, 
followed by DIPEA (0.12 mmol, 21 µl) and the amino acid was 
activated for 30 sec prior to coupling. The resin was bubbled 
with N2. A single treatment of 1 h was used for all amino acids. 
The Fmoc group was deprotected with 20 % piperidine / DMF 
(v/v, 1 mL) for 10 min. Couplings were checked using the 
ninhidrin test. The resin was washed with DMF (6 × 1 mL) at the 
end of each coupling. The peptidyl-resin was dried under 
ChemBioChem 10.1002/cbic.201600406
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vacuum and the peptide was cleaved from the resin with the 
reagent cocktail: 81 % trifluoroacetic acid (TFA), 5 % phenol, 
5 % thioanisol, 5.5 % water, 2 % dimethylsulfide, and 1.5 % 
ammonium iodide (2.5 mL) for 2 h. 
The TFA solution containing the peptide was concentrated under 
vacuum to a minimal volume, added over cold Et2O and 
precipitated by centrifugation. The supernatant was removed 
and the residue was dissolved in 20 mL of ACN/H2O (1:1) 0.1% 
TFA (HPLC buffer) and lyophilized. Peptides were used for the 
assays without further purification. 
 
BotP Proteolysis Reactions  
Substrate peptides (100 μM) were incubated with M2+ (100 μM) 
and BotP (5 μM) at 37 °C, 200 rpm. The reactions were analyzed 
at the time intervals specified via LC-MS. 
 
LC-MS 
High Performance Liquid Chromatography-Mass Spectrometry 
(HPLC-MS) (Thermo Ultimate 3000 RSLC, coupled to a Bruker 
Daltonics amaZon Electrospray Ionization (ESI)-MS ion trap 
instrument) was operated in positive ionization mode. 
Compounds were separated on a Waters Acquity BEH C18 
column (50 x 2.1 mm; 1.7 µm particle diameter) at a flow rate of 
600 ml min-1 and 45 °C by a linear gradient with (A) H2O + 0.1 % 
formic acid (FA) to (B) acetonitrile (ACN) + 0.1 % FA at a flow 
rate of 600 µl min-1 and 45 °C. The gradient was initiated by 
a 0.33 min isocratic step at 5 % B, followed by an increase to 
95 % B in 9 min to end up with a 1 min flush step at 95 % 
B before re-equilibration with initial conditions. Detection was 
carried out by both diode array (DAD) and ESI-MS. Extracted 
ion chromatograms were generated for the expected mass +/- 
0.5 m/z. The amount of substrate and the product were analysed 
using peak area. 
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Figure 1. Bottromycin A2 is derived from a ribosomally synthesized precursor 
peptide BotA (black), containing a core peptide (black) and a C-terminal 
follower sequence (green). The precursor peptide undergoes a series of post-
translational modifications to become the natural product Bottromycin A2. The 
genes within the gene cluster are coloured according to the modifications their 
gene products are proposed to catalyse
[5]
. The order of the modifications have 
been reported and include proteolysis either side of the core peptide (green), 
heterocyclisation of the C-terminal cysteine within the core peptide (purple) 
oxidation of the resultant thiazoline to thiazole (red), Cβ-methylation (dark-
blue), O-methylation (light-blue), and macrocyclisation (orange). Epimerisation 
(pink) is likely spontaneous
[5]
. 
 
Figure 2.  Cartoon representation of the crystal structure of BotP. A) BotP 
hexamer. For clarity individual monomers are colored green, yellow, cyan, pink, 
red and purple. B) BotP monomer depicting the characteristic ‘comma’ shape. 
The variable N-terminal domain is shown in blue and the catalytic C-terminal 
domain is shown in green. A chloride ion (in place of the bicarbonate ion in 
other LAPs) is shown as a yellow sphere. C) The active site of the BotP-Mn
2+
 
complex. Conserved catalytically important residues are shown as green 
sticks, Mn
2+
 ions as grey spheres and bicarbonate as green sticks. Difference 
electron density (F0-Fc) contoured to 3σ with phases calculated from a model 
that was refined in the absence of metal ions is shown as a blue isomesh. 
 
Figure 3. A) Relative proteolysis rate of a truncated version of BotA (MGPVV) 
by BotP in the presence of different metal ions. Using BotP-Co
2+
 we tested 
different residues in the P1 (B), P1’ (C) and P2’ (D) position. The reactions 
were monitored at specific time points by LC-MS. For each time point the 
amount of substrate and product were determined, and the % conversion was 
calculated. Results for full-length BotA are analogous (Figure S3). 
 
Figure 4. Model of substrate peptide MGPV (cyan) with BotP-Mn
2+
 (green). A) 
Cartoon representation. B) Ligplot representation. Hydrogen bonds and ligand 
bonds are shown as red dashes. Mn
2+
 ions are shown as grey spheres, the 
bicarbonate ion (BCT) is only shown in A since it does not interact directly with 
substrate or metal ions. 
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Table 1. Data 
Collection and 
Refinement 
Statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BotP_apo BotP-Mn
2+ 
Resolution 
range (Å) 
24.22 - 1.76  
(1.82 - 1.76) 
47.21 - 2.32  
(2.38 - 2.32) 
Space group P 63 2 2 P 63 2 2 
Unit cell 
152.42 
152.42 
100.90  
90 90 120 
151.51 
151.51 
101.19  
90 90 120 
Total reflections 
638232 
(97638) 
1139364 
(77380) 
Unique 
reflections 
68447 
(6724) 
30149 
(2166) 
Multiplicity 9.3 (8.9) 37.8 (35.7) 
Wavelength (Å) 0.92 1.89 
Completeness 
(%) 
99.96 
(99.96) 
100.00 
(99.90) 
Mean I/sigma(I) 17.0 (3.3) 26.8 (5.9) 
Wilson B-factor 22.16 21.79 
R-merge 
0.067 
(0.543) 
0.142 
(0.736) 
R-work 
0.1816 
(0.2444) 
0.1762 
(0.1965) 
R-free 
0.2000 
(0.2674) 
0.1897 
(0.1983) 
Number of non-
hydrogen atoms 
3821 3640 
  
macromolecules 
3358 3304 
  ligands 11 6 
  water 452 330 
Protein residues 457 455 
RMS(bonds) 0.008 0.008 
RMS(angles) 1.32 1.27 
Average B-
factor 
27.00 31.00 
  
macromolecules 
25.00 30.26 
  ligands 49.20 23.17 
  solvent 41.40 38.61 
One crystal was used per dataset. Values in 
parenthesis are for the highest resolution shell. 
       ∑     ∑ |       〈      〉|  
∑     ∑        , where        is the intensity of an 
individual measurement and 〈      〉  is the 
average intensity from multiple observations. 
      ∑ ||    |   |      ||  ∑        |    | (      
calculated in the same manner by using 5% of 
the reflection data chosen randomly and omitted 
from the start of refinement). 
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